Notification of Preliminary Results

RNS Number : 0672R

Alliance Pharma PLC

26 February 2019

 

26 February 2019

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

Notification of Preliminary Results

Alliance Pharma plc (AIM: APH), the international healthcare group, will announce its preliminary results for the year ended 31 December 2018 on Tuesday 26 March 2019.

A briefing for analysts will be held at 11.00am on the morning of the results at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.

To access a webcast of the analyst presentation, please log on to the following web address several minutes before 11.00am on the day of the results:

http://webcasting.buchanan.uk.com/broadcast/5c6e8e68e6e1d92d38f4f7e1

For more information, please contact Buchanan on 020 7466 5000 or email [e-mail].

For further information:

Alliance Pharma plc	+ 44 (0)1249 466966
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk
Buchanan	+ 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah Ratcliff
Numis Securities Limited	+ 44 (0)20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield
Corporate Broking: James Black

Investec Bank plc	+ 44 (0)20 7597 5970
Corporate Finance: Daniel Adams / Ed Thomas
Corporate Broking: Patrick Robb / Tejas Padalkar

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with affiliate offices in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.

We currently own or license the rights to more than 90 pharmaceutical and consumer healthcare products, which are managed on a portfolio basis according to their growth potential. Promotional investment is focussed on a small number of brands with significant international or multi-territory reach. The remainder of the portfolio comprises products which are sold in a limited number of local markets and require little or no promotional investment.

Our tried and tested 'Buy and Build' strategy, allows us to benefit both from organic growth opportunities and from enhancing our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our website:  www.alliancepharmaceuticals.com  

 

END

 

 

NORDELFLKLFEBBB